Based near Lugano in Switzerland, 1MED is a fast-growing clinical research organisation that helps MedTech companies secure regulatory approval for new medical devices and pharmaceuticals, providing specialist services including regulatory strategy, clinical trial management and quality assurance services.
FRP’s debt advisory team advised Apposite Capital on sourcing a stretched senior financing package to support the leveraged acquisition, and to provide further financial firepower to support a buy-and-build strategy. Financial details of the investment are undisclosed.
Apposite Capital will work with the 1MED management team to continue to strengthen and widen the company’s service offering and further expand its geographic coverage.
David Porter, founding partner at Apposite Capital, says: “We are very excited by the growth prospects of 1MED. The company is well-placed to be the partner of choice for an ever-evolving industry with increasingly complex clinical and regulatory requirements. We were impressed by the highly skilled and visionary team and look forward to working with them to unlock 1MED’s full potential.”
Tom Cox, debt advisory partner at FRP, adds: “We are delighted to have been able to help source and negotiate a package to support this deal, which will maximise Apposite’s ability to grow the business. Apposite has a wealth of experience in the healthcare sector and is the perfect match for 1MED. David and the team’s appetite, expertise and resources will help 1MED go from strength to strength, and I am sure this is just the start of their success story together.”
Advisers to Apposite Capital on the deal included EY, PMSI Consulting, Trowers Hamlins, and Baker McKenzie.
Advisers to 1MED included Credit Suisse AG, Fidinam & Partners, Lexsential and Druces.
